The Potential Benefits of HPV E6/E7 mRNA Test in Cervical Cancer Screening in China
Autor: | Peng Wang, Zhen Guo, You-Lin Qiao, Dong-Mei Zhao, Zeni Wu, Qiong Chen, Shaokai Zhang, Xibin Sun, Pei-Pei Guo, Le-Ni Kang, Xiaoqin Cao, Jiangong Zhang, Man-Man Jia |
---|---|
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Cancer Research medicine.medical_specialty cervical cancer mRNA specificity Cervical cancer screening lcsh:RC254-282 Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine Cytology parasitic diseases medicine Original Research Colposcopy Cervical cancer Messenger RNA medicine.diagnostic_test business.industry Clinical performance Gold standard (test) lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens HPV – human papillomavirus medicine.disease sensitiviity 030104 developmental biology Oncology 030220 oncology & carcinogenesis Histopathology business |
Zdroj: | Frontiers in Oncology Frontiers in Oncology, Vol 10 (2020) |
ISSN: | 2234-943X |
Popis: | This study aims to evaluate the clinical performance of the HPV E6/E7 mRNA test in cervical cancer screening in China. A hospital-based study was conducted with mRNA, DNA, and liquid-based cytology (LBC) as primary screening tests. Each woman with a positive result received colposcopy with lesion-targeted-biopsy. Histopathological diagnosis was used as the gold standard. The total agreement of HPV DNA and mRNA was 90.7% (95%CI: 87.9, 92.9) with a kappa value of 0.81. The positive rates of HPV DNA, mRNA, and LBC increased with the severity of histopathology diagnosis, from 25.5%, 19.1%, and 11.4% in normal to 100.0% in SCC, respectively. The sensitivities for mRNA to detect CIN2+ and CIN3+ were 93.8% (95%CI: 89.7-96.4) and 95.7% (95%CI: 91.3-97.9), respectively, which were not different from HPV DNA testing (95.7% [95%CI: 92.0-97.7], 96.3% [95%CI: 92.1-98.3]), but higher than LBC (80.4% [95%CI: 74.5-85.2] and 88.8% [95%CI: 83.0-92.8]). The specificities for mRNA to detect CIN2+ (79.0% [95%CI: 74.2-83.0]) and CIN3+ (70.5% [95%CI: 65.7-74.9]) were higher than HPV DNA testing (71.0% [95%CI: 65.9-75.7], 62.8% [95%CI: 57.8-67.5]), but lower than LBC (84.5% [95%CI: 80.1-88.0] 79.8% [95%CI: 75.4-83.6]). All tests were more effective in women older than 30 years. HPV mRNA test showed excellent agreement with the DNA test, with similar sensitivity and a higher specificity in detecting high-grade cervical lesions. It is promising that mRNA test could be used for the national cervical cancer screening to reduce false positive without losing sensitivity. |
Databáze: | OpenAIRE |
Externí odkaz: |